Yi Zheng, PhD

Biography & Affiliation Education Publications

Director, Experimental Hematology and Cancer Biology

Institute Co-Director, Cancer and Blood Diseases Institute

Marjory Johnson Endowed Chair of Drug Discovery

Professor, UC Department of Pediatrics

yi.zheng@cchmc.org

513-636-0595

513-636-3768

Visit the Zheng Lab

Biography & Affiliation

Research Interests

Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases

Science Blog

CASIN May Improve the Odds for Bone Marrow Transplants

Yi Zheng, PhD6/30/2019

Education

BS: Tsinghua University, Beijing, China, 1986.

MS: Cornell University, Ithaca, NY, 1988.

PhD: Cornell University, Ithaca, NY, 1991.

Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.

Publications

Selected Publication

Rho GTPase-Activating proteins in cancer. Grogg, MW; Zheng, Y. The Rho GTPases in Cancer. : Springer New York; Springer New York; 2010.

The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors. Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al. Nature Communications. 2019; 10.

The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors. Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al. Nature Communications. 2019; 10.

Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis. Zahra, FT; Sajib, MS; Ichiyama, Y; Akwii, RG; Tullar, PE; Cobos, C; Minchew, SA; Doci, CL; Zheng, Y; Kubota, Y; et al. Scientific Reports. 2019; 9.

Ablation of RhoA impairs Th17 cell differentiation and alleviates house dust mite-triggered allergic airway inflammation. Yang, JQ; Kalim, KW; Li, Y; Zheng, Y; Guo, F. Journal of Leukocyte Biology. 2019; 106:1139-1151.

KRas^G12D expression in the bone marrow vascular niche affects hematopoiesis with inflammatory signals. Hochstetler, CL; Feng, Y; Sacma, M; Davis, AK; Rao, M; Kuan, CY; You, LR; Geiger, H; Zheng, Y. Experimental Hematology. 2019; 79:3-15.e4.

Inhibition of Rho-Kinase Downregulates Th17 Cells and Ameliorates Hepatic Fibrosis by Schistosoma japonicum Infection. Zhou, W; Yang, Y; Mei, C; Dong, P; Mu, S; Wu, H; Zhou, Y; Zheng, Y; Guo, F; Yang, J. Cells. 2019; 8:1262-1262.

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma. Nguyen, P; Chakrabarti, J; Li, Y; Kalim, KW; Zhang, M; Zhang, L; Zheng, Y; Guo, F. Frontiers in Oncology. 2019; 9.

Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization. Liu, W; Du, W; Shang, X; Wang, L; Evelyn, C; Florian, MC; Ryan, MA; Rayes, A; Zhao, X; Setchell, K; et al. Leukemia. 2019; 33:749-761.

Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation. Yang, J; Kalim, KW; Li, Y; Duan, X; Nguyen, P; Hershey, GK K; Kroner, J; Ruff, B; Zhang, L; Salomonis, N; et al. Clinical and Experimental Allergy. 2019; 49:92-107.